Document Detail

Preventing herpes simplex virus transmission to the neonate.
MedLine Citation:
PMID:  15319088     Owner:  NLM     Status:  MEDLINE    
Neonatal herpes simplex virus (HSV) infection can have severe consequences. Skin, eye and mouth infection is rarely fatal, but disseminated or central nervous system (CNS) disease has a mortality rate of 80% in the absence of therapy, and most surviving infants have neurological sequelae. Aciclovir therapy can improve the outcome of neonatal herpes, but is often delayed due to the early non-specific symptoms of the disease. Even with early therapy, some infants develop disseminated infection or CNS complications. The virus is usually vertically transmitted to the neonate from an infected mother during delivery. As such, the optimal strategy for reducing the morbidity of neonatal herpes is to prevent the neonate from acquiring HSV infection at delivery. The highest risk of neonatal infection occurs when the mother sheds HSV at labour, which happens more frequently in women who acquire genital herpes in the third trimester. Therefore, one approach for reducing maternal-fetal transmissions is to prevent HSV acquisition in late pregnancy. Definitive classification of genital HSV infection during pregnancy as either primary, non-primary first episode or recurrent can be accomplished only when clinical evaluation is accompanied by laboratory testing, including the use of gG-specific serological tests. The serological status of the mother's sexual partner should be considered when determining her risk of infection. The use of weekly viral cultures in pregnant women with confirmed genital herpes is not warranted, as they do not predict an infant's risk of acquisition of HSV at delivery and are not cost-effective. High-risk susceptible women should be counselled about abstinence and reducing oral-genital contact near term. Observational studies suggest that caesarean section can reduce transmission of neonatal herpes, and is warranted for women who shed HSV at delivery, although different countries vary in their approach to caesarean sections and so universal recommendations are not available. If maternal antiviral therapy is considered, the potential benefits of treatment should be balanced against potential adverse outcomes for mother and fetus, although it may be warranted when the mother has severe or life-threatening disease. Studies on the use of antiviral prophylaxis in women with known recurrences at labour are ongoing. Invasive fetal monitoring can increase the risk of neonatal herpes, and should only be used in HSV-2 seropositive women for defined obstetrical indications.
Zane Brown
Related Documents :
20813278 - Progress toward improved understanding of infection-related preterm birth.
9002308 - Chronic respiratory failure after acquired cytomegalovirus infection in a very low birt...
7796228 - Administration of intravenous immunoglobulins for prophylaxis or treatment of infection...
21319248 - Season of birth and subsequent body size: the potential role of prenatal vitamin d.
19772968 - Categorizing neonatal deaths: a cross-cultural study in the united states, canada, and ...
17089868 - Retinopathy of prematurity.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Herpes : the journal of the IHMF     Volume:  11 Suppl 3     ISSN:  0969-7667     ISO Abbreviation:  Herpes     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-08-20     Completed Date:  2004-10-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9801722     Medline TA:  Herpes     Country:  England    
Other Details:
Languages:  eng     Pagination:  175A-186A     Citation Subset:  IM    
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195-6460, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / adverse effects
Cesarean Section
Herpes Simplex / prevention & control,  transmission*
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control*
Pregnancy Complications, Infectious / diagnosis,  drug therapy
Reg. No./Substance:
0/Antiviral Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevention of herpes simplex virus type 2 transmission with antiviral therapy.
Next Document:  Diagnosis of herpesvirus infections of the central nervous system.